Angiogenesis inhibitors are a new class of drugs, for which the general rules involving
conventional chemotherapy might not apply. The successful translation of angiogenesis …

Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …

The process of angiogenesis encompasses the growth and regression of capillary blood
vessels. Angiogenesis is finely regulated at the molecular and genetic levels, not unlike …

A substantial number of clinical trials using antiangiogenic therapies are ongoing worldwide.
How to achieve the maximum benefit from these therapies and how to monitor patient …

Besides its role as an essential regulator of physiologic and pathologic angiogenesis,
vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of …

Thalidomide, bortezomib, and lenalidomide have recently changed the treatment paradigm
of myeloma. In young, newly diagnosed patients, the combination of thalidomide and …

When the FDA commissioner announced in February 2004 the approval of Avastin for the
treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of …

There is accumulating evidence that leukemias and other hematologic diseases are
angiogenesis-dependent. Therefore, angiogenesis inhibitors may be useful adjuncts to …

Abstract Development of antiangiogenic therapies would be significantly facilitated by
quantitative surrogate pharmacodynamic markers. Circulating peripheral blood endothelial …

The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but
not yet demonstrated in a randomised‐controlled trial. A systematic review of the published …